

A Process Development Strategy Providing Flexibility While Balancing Cost and Speed without Sacrificing Quality

Martin Allen, Bioprocess Research and Development, Pfizer, Chesterfield, MO

Platform process development approaches work well for large molecule therapeutics including monoclonal antibodies (mAbs). variety of modalities ranging from mAbs to antibody drug conjugates to fusion proteins and native molecules. To efficiently prosecute this diverse portfolio we apply approaches that balance risk, timeline pressures, and cost without sacrificing